Nogo, Danica
Jasrai, Ashitija K.
Kim, Haeun
Nasri, Flora
Ceban, Felicia
Lui, Leanna M. W.
Rosenblat, Joshua D.
Vinberg, Maj
Ho, Roger
McIntyre, Roger S.
Article History
Received: 22 August 2021
Accepted: 23 February 2022
First Online: 15 March 2022
Declarations
:
: RSM has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC); speaker/consultation fees from Lundbeck, Janssen, Alkermes, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie, Atai Life Sciences. RSM is a CEO of Braxia Scientific Corp. JDR has received research grant support from the Canadian Cancer Society, Canadian Psychiatric Association, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship, and industry funding for speaker/consultation/research fees from Janssen, Allergan, Lundbeck, Sunovion, and COMPASS. JDR is the medical director of a private clinic providing intravenous ketamine infusions and intranasal esketamine for depression. LMWL is a contractor to Braxia Scientific. MV has within the last 3 years been a consultant for Lundbeck, Janssen Cilag, and Sunovion. All other authors have no conflicts of interest to disclose.